L-arginine improves the symptoms of strokelike episodes in MELAS

Area of Science:

• Neurology
• Mitochondrial Diseases
• Vascular Biology

Background:

• Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS) is a rare genetic disorder.
• The underlying pathophysiology is hypothesized to involve impaired vasodilation in cerebral arteries.
• Nitric oxide (NO) plays a crucial role in regulating vascular tone.

Purpose of the Study:

• To investigate the therapeutic potential of L-arginine, a precursor to nitric oxide, in patients with MELAS.
• To evaluate the efficacy of L-arginine administration during acute and interictal phases of the condition.

Main Methods:

• Patients with MELAS received L-arginine intravenously during acute phases.
• Oral L-arginine supplementation was administered during interictal phases.
• Clinical outcomes, including strokelike episodes, were assessed.

Main Results:

• Intravenous L-arginine infusions led to significant improvement in strokelike symptoms.
• Oral L-arginine administration, particularly within 30 minutes of stroke onset, markedly decreased the frequency and severity of strokelike episodes.
• These findings support the role of impaired vasodilation in MELAS.

Conclusions:

• L-arginine shows promise as a therapeutic agent for MELAS.
• Targeting nitric oxide pathways may be a viable strategy for managing MELAS-related cerebrovascular complications.
• Early intervention with oral L-arginine could be beneficial in mitigating stroke-like episodes.